Après-demain

What Après-demain does

Après-demain SA is a private, family-owned Swiss holding group founded in 1979 and headquartered in Lausanne, operating across four interconnected divisions: Life Science, Responsible Capital Management, Impactful Capital Management, and Philanthropy. The Life Science division, operated through Debiopharm, develops and manufactures proprietary pharmaceutical compounds including Triptorelin for oncology applications (prostate and breast cancer) and precocious puberty treatment, with production scaled 440% since 2010 across facilities in Lausanne and Martigny. The group also invests in digital health through the Debiopharm Innovation Fund and pursues new drug development partnerships, including a January 2026 collaboration with GARDP for gonorrhea treatment.

The Responsible Capital Management division deploys capital through direct private equity, private debt, real estate (via Next Immobilier), and private equity funds managed through S.I.GN Partenaires SA, with a portfolio spanning healthcare facilities, renewable energy, consumer brands, and sustainable infrastructure across Europe and North America. The Impactful Capital Management division operates through Impact Healthcare SA (investing in patient care infrastructure including Clinique de Maisonneuve and Clinique de Belle-Terre) and GeneRActions Planet (deploying 20-30M CHF annually in climate solutions including renewable energy, geothermal, energy storage, and circular economy). The Philanthropy division operates Fondation Philanthropique Next, which has impacted 11.9 million beneficiaries across 11 countries since 2013 through education, micro-entrepreneurship, autism support, and humanitarian aid.

Revenue is generated through multiple streams: pharmaceutical licensing and royalties from proprietary drugs, manufacturing revenue from Debiopharm Research & Manufacturing, asset management fees from S.I.GN Partenaires SA, private equity returns, and rental income from a real estate portfolio that achieved B energy labels across all buildings with CO2 emissions 57% below Swiss average. The group is led by Thierry Mauvernay (Chairman and CEO), with the Mauvernay family maintaining controlling ownership providing long-term capital deployment flexibility. With approximately 450 employees representing 40 nationalities across five continents, Après-demain operates across Switzerland, France, Italy, Spain, Sweden, Finland, Canada, the United States, and multiple emerging markets.

Name

Après-demain

Legal name

Après-demain SA

Website

https://apres-demain.com

Company type

Private

Founded year

1979

Operating status

Operating

Headcount range

11–50 employees

Short description

Après-demain SA is a Swiss private family-owned holding group operating across Life Science (Debiopharm pharmaceutical development and manufacturing), Capital Management (private equity, debt, and real estate), Impactful Capital Management (healthcare and environmental investments), and Philanthropy, serving institutional investors, portfolio companies, and patients globally.

Ownership category

akta.pro rank

Product category

Diversified Holding & Investment Group

NAICS

Corporate, Subsidiary, and Regional Managing Offices (551114)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Pharmaceutical drug development
• Private equity investments
• Asset management services
• Impact investing
• Healthcare venture capital

Headquarters

HQ city

Lausanne

HQ country

Switzerland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Licensing and Royalties: Debiopharm acquires licenses for innovative compounds and develops them into licensed drugs. Revenue generated through licensing agreements and drug sales royalties from pharmaceutical products including Triptorelin for oncology applications.
2. Pharmaceutical Manufacturing: Debiopharm Research & Manufacturing produces pharmaceutical compounds at facilities in Lausanne and Martigny, Switzerland, serving both internal development needs and potentially external clients.
3. Asset Management Fees: Management of diversified investment portfolio including private equity, private debt, and real estate generates management fees and carried interest from fund operations through S.I.GN Partenaires SA.
4. Private Equity Returns: Returns generated through direct private equity investments, co-investments alongside partners, and long-term participations in healthcare, environmental technology, and other impact sectors.
5. Real Estate Income: Rental income and capital appreciation from real estate portfolio managed by Next Immobilier, with focus on energy efficiency and sustainable buildings.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Après-demain is a private, family-owned Swiss holding group operating four main divisions: (1) Life Science through Debiopharm for pharmaceutical drug development and manufacturing in oncology and bacterial infections including the proprietary Triptorelin compound; (2) Responsible Capital Management offering direct private equity, private debt, fund investments, and real estate management; (3) Impactful Capital Management through Impact Healthcare SA and GeneRActions Planet for healthcare and environmental impact investments; and (4) a Philanthropy division operating Fondation Philanthropique Next. The group deploys capital across healthcare, renewable energy, and impact sectors globally.

Product overview

Après-demain is a Swiss private family-owned group consisting of four main divisions: (1) Life Science (Debiopharm) covering drug development in oncology and bacterial infections, drug manufacturing, and digital health investment; (2) Responsible Capital Management encompassing Direct Private Equity, Private Debt, Private Equity Funds (S.I.GN Partenaires SA), Long-Term Participations, Finance, Real Estate (Next Immobilier), and Compliance & Operations; (3) Impactful Capital Management including Impact Healthcare SA and GeneRActions Planet for healthcare and environmental impact investments; and (4) a Philanthropy Division comprising Fondation Philanthropique Next, the Patient Quality of Life Challenge, and the Debiopharm Chair for Family Philanthropy. The group operates primarily as an investment holding company rather than a technology product company.

Differentiator

Problem solved

Functional benefit

Brands

• Debiopharm: Life Science division active in drug development (oncology and bacterial infections), drug manufacturing (Debiopharm Research & Manufacturing), and digital health investment (Debiopharm Innovation Fund)
• Impact Healthcare SA
• GeneRActions Planet
• Fondation Philanthropique Next

Products and services

• Debiopharm Life Science Division Life Science division comprising three subsidiaries: Debiopharm International (drug development in oncology and bacterial infections), Debiopharm Research & Manufacturing (drug manufacturing at Lausanne and Martigny facilities), and Debiopharm Innovation Fund (digital health investment). Products include the proprietary Triptorelin compound used for prostate cancer, breast cancer, and precocious puberty treatment.
• Triptorelin Pharmaceutical Compound Proprietary GnRH agonist compound manufactured by Debiopharm for treatment of prostate cancer, breast cancer, and precocious puberty. Licensed to global pharmaceutical partners for commercialization with production scaled 440% since 2010.
• Responsible Capital Management

Quantifiable outcome

• 11.9 million people impacted by philanthropy since 2013
• +5 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core and secondary.

• Clinique de Belle-TerrecoreStrategic or Co-development Partner · 14 April 2026Impact Healthcare invested in Clinique de Belle-Terre in Geneva, inaugurated April 2026, as part of continued deployment of patient support strategy throughout care journey.
• GARDP (Global Antibiotic Research & Development Partnership)coreStrategic or Co-development Partner · 13 January 2026Debiopharm and GARDP partnered in January 2026 to advance development of a novel gonorrhea drug, combining Debiopharm's pharmaceutical development expertise with GARDP's global health mission to address antimicrobial resistance.
• Next ImmobiliercoreStrategic or Co-development Partner · 9 October 2025Next Immobilier (After-demain subsidiary) is co-leading operational development of 'Les Vignes' district in Rolle, Switzerland, as part of real estate development strategy.
• Hoppen GroupcoreStrategic or Co-development Partner · 22 June 2023After-demain invested in Hoppen, French leader in phygital patient support solutions, alongside existing investors Extens and Geneo. Hoppen has supported 5M+ patients and was nominated for French Tech 2030.
• SiparexcoreStrategic or Co-development Partner · 12 October 2021After-demain invested alongside Siparex and management team in Destia's LBO. Siparex took majority control of Destia, French leader in homecare services, with 100+ agencies and 5,000+ home care assistants across France.
• Clinique de MaisonneuvecoreStrategic or Co-development Partner · 22 April 2021Impact Healthcare (After-demain subsidiary) acquired minority stake in Clinique de Maisonneuve, recognized player in Geneva for post-acute rehabilitation care with 44 inpatient rooms and 100% outpatient center since December 2020.
• WISE Philanthropy AdvisorssecondaryImplementation/ SI/ Consulting PartnerExternal advisors Martial Paris and Etienne Eichenberger from WISE Philanthropy Advisors support Fondation Philanthropique Next's strategic planning, grant management, and impact evaluation. Both serve on Swiss Philanthropy Foundation board.
• Debiopharm Chair for Family Philanthropy (IMD)coreStrategic or Co-development PartnerPartnership with IMD business school to train philanthropists in improving social impact. Advisory board includes Cédric Mauvernay; Etienne Eichenberger also serves on the advisory board.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Debiopharm: The wholly-owned Life Science subsidiary of Après-demain itself; included to anchor direct comparability of the pharmaceutical R&D and manufacturing operations within the broader group analysis.
• Siparex: French mid-market private equity firm; co-invested with Après-demain in Destia's LBO and frequently co-invests in similar European healthcare and impact strategies. Closest co-investment peer for the PE and Impact Healthcare activities.
• Omnes Capital: European private equity and infrastructure investor; partnered with Après-demain on Ilmatar Energy's IPP transformation. Highly comparable profile for the renewable energy and climate-infrastructure investing activity.
• Fondation de Rothschild (Edmond de Rothschild Foundation): Swiss-based family philanthropy with comparable scale, professionalized governance, and multi-generational approach to philanthropic capital deployment. Closest peer for the Fondation Philanthropique Next model.

Broad incumbents

• Ferring Pharmaceuticals: Swiss-headquartered, privately-held specialty pharmaceutical company focused on reproductive health, urology, and oncology — directly comparable to Debiopharm's Triptorelin franchise and oncology/uro-oncology pipeline.
• Ipsen: Global specialty pharma with leading GnRH agonist franchise (Decapeptyl/Triptorelin). Closest large-pharma competitor to Debiopharm's Triptorelin licensing economics and oncology focus.
• Vontobel / Vontobel Wealth Management: Swiss diversified financial group with private markets and impact investing capabilities. Comparable to Après-demain's Responsible Capital Management and Impactful Capital Management divisions in terms of Swiss base and multi-asset family-office-style offerings.

Emerging players

• Aenova Group: European pharmaceutical contract development and manufacturing organization (CDMO) with comparable scale and European manufacturing footprint to Debiopharm Research & Manufacturing's Martigny/Lausanne operations.
• PolyPeptide Group: Swiss-based specialty manufacturer of peptide-based APIs, including gonadotropin-releasing hormone agonists. Directly comparable manufacturing technology base to Debiopharm's Triptorelin production.

Regional players

• Cofinimmo: Belgian healthcare REIT that acquired 24 elderly care facilities from BILT (an Après-demain-related vehicle) for €340M+. Closest European listed peer for the real estate and healthcare property investment activity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.apres-demain.com%2Fen%2F
• LinkedInlinkedin.com/company/apr%C3%A8s-demain-sa

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Après-demain